Forchheim, Germany Clinical Trials

A listing of Forchheim, Germany clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 46 clinical trials
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. This study will evaluate how well risankizumab works compared to ustekinumab. This study will assess change in Crohn's Disease Activity Index (CDAI). Risankizumab is an investigational drug being developed for the treatment of …

tumour necrosis
abdominal pain
tumor necrosis factor
Universitaetsklinikum Erlangen /ID# 223404
 (8.7 away) Contact site
  • 20 Jun, 2021
  • +393 other locations
A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Patients With Metastatic Colorectal Cancer

This is a global, randomized, double-blind, placebo-controlled, multicenter phase 3 clinical trial to compare the efficacy and safety of fruquintinib plus best supportive care (BSC) versus placebo plus BSC in patients with refractory metastatic colorectal cancer (mCRC). 687 subjects will be randomized to one of the following treatment arms in …

metastatic colorectal adenocarcinoma
Universitaetsklinikum Erlangen
 (8.7 away) Contact site
  • 30 Apr, 2021
  • +138 other locations
Comparison Between Two Dose Levels of Daunorubicin and Between One vs. Two Induction Cycles for Adult Patients With AML

The proposed trial will address two clinically important questions for younger patients with newly diagnosed acute myeloid leukemia (AML): the optimal dose of daunorubicin in induction therapy and the necessity of a second induction cycle in patients with a good response after the first induction. The primary endpoint is the …

ejection fraction
minimal residual disease
acute promyelocytic leukemia
neoadjuvant therapy
residual tumor
Universit tsklinikum Erlangen
 (9.4 away) Contact site
  • 24 Jan, 2021
  • +40 other locations
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy are at higher risk of disease recurrence. More effective treatment options are needed for this patient population. This study will examine the efficacy and safety of trastuzumab deruxtecan (T-DXd) compared with trastuzumab emtansine …

Frauenklinik der Universit t Erlangen
 (8.7 away) Contact site
  • 13 Jun, 2021
  • +422 other locations
A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer

The main purpose of this study is to measure how well abemaciclib works in participants with early breast cancer who are taking hormone therapy after surgery. Participants must have breast cancer that is hormone receptor positive (HR+) and human epidermal receptor 2 positive (HER2+). Your participation could last up to …

hormone therapy
Universit tsklinikum Erlangen
 (8.7 away) Contact site
  • 20 Jun, 2021
  • +503 other locations
Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients

The purpose of the study is to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).

progressive disease
radionuclide therapy
Universit tsklinikum Erlangen
 (8.7 away) Contact site
  • 19 Apr, 2021
  • +82 other locations
Study to Assess Efficacy and Safety of Cx601 Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn's Disease (CD)

The purpose of this study is to evaluate the combined remission of complex perianal fistulas, defined as the clinical assessment at Week 24 of closure of all treated external openings that were draining at baseline despite gentle finger compression, and absence of collections greater than (>) 2 centimeter (cm) (in …

tumour necrosis
immunosuppressive agents
certolizumab pegol
Universitatsklinikum Erlangen
 (8.7 away) Contact site
  • 28 May, 2021
  • +177 other locations
Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents

The trial B-NHL 2013 is a collaborative prospective, multi-national, multi-center, randomized trial with participating centers of the NHL-BFM group (Austria, Switzerland, Czech Republic, Germany) and the Scandinavian NOPHO group (Denmark, Finland, Norway, Sweden). The aim of the trial is to evaluate the role of rituximab in the treatment of mature …

Universit tsklinikum Erlangen, Klinik f r Kinder- und Jugendmedizin, P diatrische Onkologie / H matologie
 (8.7 away) Contact site
  • 16 Jun, 2021
  • +92 other locations
A Study of the Efficacy and Safety of Upadacitnib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies

The objective of this study is to evaluate the efficacy and safety of upadacitinib compared to placebo as induction therapy in participants with moderately and severely active Crohn's disease (CD).

mucosal inflammation
abdominal pain
immunosuppressive agents
Universitaetsklinikum Erlangen /ID# 203552
 (8.7 away) Contact site
  • 02 Jun, 2021
  • +730 other locations
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS)

Novartis Investigative Site
 (8.7 away) Contact site
  • 22 May, 2021
  • +99 other locations